Archimedes Development Ltd, a subsidiary of Archimedes Pharma Ltd the UK-based pan-European specialty pharmaceutical company, has received EU funding totalling €2.77 million, over three years, for a collaborative project to reduce the threat of an avian influenza pandemic by developing a vaccine against the avian influenza virus.
The Nasal Pandemic Influenza Vaccine (NASPANVAC) project is funded by the European Union under the FP7 scheme. The aim of the project is to develop an effective, user-friendly, stable and intranasally delivered vaccine against highly pathogenic strains of the influenza virus (HF591 and other H5 and N7 subtypes) using Archimedes’ proprietary nasal delivery platform, ChiSys® and to have demonstrated proof of principle in clinical trials during the programme.
ChiSys is a highly effective transmucosal enhancement technology able to overcome many of the limitations of other intranasal drug delivery systems. The technology is aimed at providing patients with a more acceptable, convenient and effective means of delivering medicines. A particular advantage of the technology is that antigens may be delivered as a spray at a physiological pH whilst maintaining their stability and effectiveness and potentially avoiding the need for cold chain supply. ChiSys has an established safety profile and has been shown to enhance the immune responses generated by nasally administered vaccines to a range of diseases both in pre-clinical and clinical studies. ChiSys is currently being used in a co-development programme with LigoCyte Pharmaceuticals to develop vaccines to Norovirus and Anthrax.
The three year trans-disciplinary collaborative project will involve several European research and academic institutions and small to medium enterprises, who each bring their extensive experience in various specialist fields, including, avian influenza and vaccine research, development and delivery, to the programme.